Goodwin Bio competitors

Accredited public company director. Dynamic, creative, growth and success oriented leader. Proven experience building and leading an organization from distress to profitability while increasing shareholder value 5x in 24 months.

Key experiences in leading mergers and acquisitions, working with financial institutions and markets, driving exceptional growth in revenue and profit, developing organizations, managing organizational performance, and planning strategic growth. Specialties: Mergers and acquisitions, General Management, Marketing, Sales, Quality Systems.

Executive Officer with over 20 years of transactional and operational experience in venture capital backed startups to mature fully integrated organizations in the biotechnology, medical device, and pharmaceutical industries. Completed strategic transactions & shareholder exits totaling |$530M, venture capital/royalty fundraising totaling |$70M, and public offerings (IPO and secondary) totaling |$200M. Established strategy as part of executive management teams, growing revenues to |$300M, hired and led senior (C-Level to VP level) leadership teams, and secured multiple FDA PMA, NDA, and 510(k) approvals. Functional leadership in and P&L responsibility for market development, international sales distribution, M&A/business development, R&D, regulatory & clinical affairs, manufacturing & logistics, patent & legal affairs, quality operations, facilities, finance, and information technology.Areas of expertise include: Organization Transformation, R&D, Strategic Planning, Integrating Acquisitions and Products, Business Development, Investor & Shareholder Relations, Board of Directors and KOL Engagement, Crisis Management & Restructuring, Product Development, FDA & Global Regulatory Approvals, Lean & Continuous Improvement, Financial Analysis, and P&L/Cost Management.

Terry Rich works at NUVASIVE INC and a President/CEO at RTI SURGICAL, INC. and Board Member at RTI SURGICAL, INC.. He has worked as Board Member at ALPHATEC HOLDINGS, INC.; Senior VP:Sales at NUVASIVE INC; and President/COO at ALPHATEC HOLDINGS, INC.. Terry attended Rutgers University.

Mr. Dominick C. Colangelo joined Promedior in December 2008 with fifteen years of pharmaceutical industry experience, including nearly a decade with Eli Lilly and Company. During his career, Mr. Colangelo has held a variety of executive positions of increasing responsibility in finance, product development, pharmaceutical operations, and corporate business development. During his tenure at Eli Lilly and Company, Mr. Colangelo held positions as an international tax attorney in the finance organization and as Director of Strategy and Business Development for Lilly’s Diabetes and Growth Disorders Product Group. He also served as a founding Managing Director of Lilly Ventures. Mr. Colangelo received a B.S.B.A. degree in Accounting from the State University of New York at Buffalo and a J.D. degree from the Duke University School of Law.

John Ducker is a Plant Manager at Fresenius SE Group, President/CEO at Fresenius Kabi USA, and Director at FRANCESCA'S HOLDINGS CORP. He has worked as Board Member at FRESENIUS KABI ONCOLOGY LIMITED, President/CEO at App Pharmaceuticals Inc., and Board Member at Dabur Pharma Co. Ltd. John studied at University of Cambridge.

Avi Pelossof was appointed Global President of our infectious disease business unit in March 2013, after serving as Vice President of that business from February 2008 to February 2013. Mr. Pelossof joined Alere as Vice President, Blood-Borne Pathogens in January 2007 and served in that role until January 2008. Mr. Pelossof has more than 20 years of experience in diagnostics, global health and international finance, including senior roles at Chembio Diagnostic Systems, a manufacturer of diagnostic tests for infectious diseases, and Citigroup.